-
Tesla and
CureVac filed a
joint patent on the technology. In August, Musk
reviewed the
project with
Curevac while in Germany. By 2017,
CureVac had received...
- The
CureVac COVID-19
vaccine (abbreviated CVnCoV) was a COVID-19
vaccine candidate developed by
CureVac N.V. and the
Coalition for
Epidemic Preparedness...
-
additional companies such as
Viacyte (part of Vertex), Nkarta, Capsida,
Curevac, and others.
CRISPR Therapeutics has
drugs approved and in development...
-
including Deutsche Post,
Deutsche Telekom, Commerzbank, Lufthansa, and
CureVac. In 2013, KfW
agreed to help
establish a
Portuguese financial institution...
- (€955 million). In July 2020, GSK
acquired a 10%
stake in
German biotech company CureVac. In
March 2018, GSK
announced that it has
reached an
agreement with Novartis...
-
review of
CureVac's COVID-19
vaccine (CVnCoV)".
European Medicines Agency (EMA) (Press release). 1
December 2020.
Retrieved 12
February 2021. "
CureVac s****s...
- (BNT162b2), and by
Moderna (mRNA-1273). The
zorecimeran vaccine developed by
Curevac, however, uses
unmodified mRNA,
instead relying on
codon optimization to...
-
Behring (subsidiary of CSL; 1904– ) CSPC (1992- ) CSPC
Zhongrun (1989– )
CureVac (2000– )
Cyclacel (1997– )
Cytokinetics (1997– )
CytRx (1985– ) Daewoong...
-
concerning the use of RNA and is a
founder of the
German biotechnology company CureVac. He
created the
initial technology used in RNA
vaccines and has reportedly...
- the Pfizer–BioNTech and
Moderna vaccines. The
CVnCoV RNA
vaccine from
CureVac failed in
clinical trials.
Severe allergic reactions are rare. In December...
